Which antipsychotic medications are associated with neutropenia?

Antipsychotics Associated with Neutropenia

Clozapine is the antipsychotic most strongly associated with neutropenia, requiring mandatory absolute neutrophil count (ANC) monitoring, but other antipsychotics including perazine, quetiapine, olanzapine, risperidone, zuclopenthixol, aripiprazole, and lurasidone can also cause this potentially fatal adverse effect 1, 2.

Primary Offender: Clozapine

Clozapine carries the highest risk for neutropenia among all antipsychotics, with an incidence of 1.57 per 1,000 patients exposed 2. The 2026 global consensus guidelines establish:

• ANC threshold for considering cessation: 1.0×10⁹ cells/L (or 0.5×10⁹ cells/L for patients who are DARC/ACKR1-null with benign ethnic neutropenia) 1
• Weekly ANC monitoring for first 18 weeks, then monthly monitoring until 2 years 1
• After 2 years of stable treatment, routine ANC monitoring can be discontinued 1
• Annual complete blood count remains recommended for screening hematological malignancies 1

The risk of clozapine-induced severe neutropenia declines significantly over time, with most cases occurring in the first 3 months of treatment 2.

Other Implicated Antipsychotics

Based on pharmacovigilance data from 333,175 psychiatric inpatients 2:

Second-Generation Antipsychotics (by risk level):

• Quetiapine: 0.23 per 1,000 exposed (15 documented cases) 2
• Olanzapine: 0.13 per 1,000 exposed (7 cases) 2, 3
• Risperidone: Multiple case reports of severe neutropenia 4, 5, 3
• Aripiprazole: Documented cases of neutropenia 3
• Lurasidone: Dose-dependent neutropenia reported 5

First-Generation Antipsychotics:

• Perazine: Second highest relative risk after clozapine at 0.52 per 1,000 exposed (8 cases) 2
• Zuclopenthixol: Case reports of neutropenia 6

Critical Clinical Considerations

Cross-Susceptibility Pattern

Patients who develop neutropenia with one antipsychotic are at significantly higher risk with subsequent antipsychotics 6, 3. A documented case showed sequential neutropenia with zuclopenthixol followed by clozapine 6, and another with olanzapine, quetiapine, risperidone, and aripiprazole 3.

Timing of Onset

Neutropenia most commonly occurs within the first 3 months of treatment across all antipsychotics 2. However, it can occur at any time during therapy.

Alternative Causes to Exclude

Before attributing neutropenia to antipsychotics, consider 1:

• Co-administration of valproic acid
• Chemotherapy agents
• Active infection or inflammatory disorders
• Nutritional deficiencies
• Primary hematological conditions

Management Strategy

When neutropenia develops with non-clozapine antipsychotics:

1. Discontinue the offending agent immediately - ANC typically normalizes after cessation 6, 4
2. Consider manufacturer change before switching medications - inactive ingredients may contribute to neutropenia; switching to brand name or alternative generic formulation may resolve the issue 7
3. Monitor ANC closely with any subsequent antipsychotic given cross-susceptibility risk 3
4. Consider lithium augmentation - may help maintain ANC in patients requiring antipsychotic therapy 6

Protective Factors

Patients with ANC consistently >2,000/µL during the first year of treatment and absence of severe medical conditions have significantly lower risk of developing neutropenia, even with clozapine 8.

Sex Differences

Neutropenia occurs more frequently in women, though agranulocytosis shows no sex difference 2.